17722-52-0

Usage

Uses

Used in Pharmaceutical Industry:
4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID is used as a pharmaceutical intermediate for its potential role in the development of new drugs. Its interaction with biological systems makes it a valuable component in the creation of medications that could address various health conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID serves as a subject of study for its potential anti-inflammatory and analgesic properties. The exploration of these properties is crucial for advancing the understanding of its therapeutic potential and for formulating more effective treatment options.
Used in Drug Development:
4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID is utilized as a key component in drug development, where its structure and properties are harnessed to create innovative pharmaceuticals. 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID's ability to interact with biological systems is particularly beneficial in designing drugs that can target specific pathways or receptors within the body.

InChI:InChI=1/C10H10ClNO3/c11-7-1-3-8(4-2-7)12-9(13)5-6-10(14)15/h1-4H,5-6H2,(H,12,13)(H,14,15)

Upstream product

• 108-30-5 succinic acid anhydride 
• 106-47-8 4-chloro-aniline 
• 108-31-6 maleic anhydride 

Downstream Products

• 80452-55-7 7-chloro-1,3,4,5-tetrahydro-2H-1-benzazepine-2,5-dione 
• 1631-29-4 N-(4-chlorophenyl)maleimide 
• 17722-53-1 3-(4-Chlor-phenylcarbamoyl)-propionsaeure-aethylester 
• 1375737-05-5 N¹-(4-chlorophenyl)-N⁴-(3-(4-hydroxypiperidin-1-yl)propyl)succinamide 
• 1376434-70-6 N₁-(4-chlorophenyl)-N₄-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(piperidin-2-yl)methyl)succinamide hydrochloride 
• 1375737-14-6 N¹-(4-chlorophenyl)-N⁴-(1-((2-methylimidazo[1,2-a]pyrimidin-3-yl)methyl)piperidin-4-yl)succinamide 
• 1375737-06-6 N¹-(4-chlorophenyl)-N⁴-(2-(3-methylpiperidin-1-yl)benzyl)succinamide 
• 1375737-03-3 N¹-(4-chlorophenyl)-N⁴-(4-(morpholinosulfonyl)benzyl)succinamide 
• 1375737-02-2 N¹-(4-chlorophenyl)-N⁴-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(pyrrolidin-2-yl)methyl)succinamide hydrochloride 
• 1375737-13-5 N¹-(4-chlorophenyl)-N⁴-(3-(2-methyl-1H-imidazol-1-yl)propyl)succinamide formate 
• 1375737-09-9 N¹-(4-chlorophenyl)-N⁴-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)succinamide formate 
• 1375737-11-3 N¹-(4-chlorophenyl)-N⁴-(3-(2-isopropyl-1H-imidazol-1-yl)propyl)succinamide formate 
• 1375737-07-7 N¹-(4-chlorophenyl)-N⁴-(1-morpholinobutan-2-yl)succinamide 
• 1375737-04-4 N¹-(4-chlorophenyl)-N⁴-(3-(3-hydroxypiperidin-1-yl)propyl)succinamide 

Relevant academic research and scientific papers

Synthesis and comprehensive structural studies of a novel amide based carboxylic acid derivative: Non–covalent interactions

The presented work studies the geometric and electronic structures of the crystalline network of a novel amide based carboxylic acid derivative, N–[(4–chlorophenyl)]–4–oxo–4–[oxy] butane amide, C10H10NO3Cl (1), constructed

Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway

Triple-negative breast cancer (TNBC) has an unfavorable prognosis attribute to its low differentiation, rapid proliferation and high distant metastasis rate. PI3K/Akt/mTOR as an intracellular signaling pathway plays a key role in the cell proliferation, m

Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory

Alzheimer's disease (AD) is clearly linked to the decline of acetylcholine (ACh) effects in the brain. These effects are regulated by the hydrolytic action of acetylcholinesterase (AChE). Therefore, a central palliative treatment of AD is the administration of AChE inhibitors although additional mechanisms are currently described and tested for generating advantageous therapeutic strategies. In this work, we tested new arylamides and arylimides as potential inhibitors of AChE using in silico tools. Then, these compounds were tested in vitro, and two selected compounds, C7 and C8, as well as propranolol showed inhibition of AChE. In addition, they demonstrated an advantageous acute toxicity profile compared to that of galantamine as a reference AChE inhibitor. in vivo evaluation of memory performance enhancement was performed in an animal model of cognitive disturbance with each of these compounds and propranolol individually as well as each compound combined with propranolol. Memory improvement was observed in each case, but without a significant additive effect with the combinations.

An expeditious synthesis of imides from phthalic, maleic and succinic anhydrides and chemoselective C=C reduction of maleic amide esters

Phthalic, maleic and succinic anhydrides have been reacted with aromatic amines to obtain the corresponding monoacid monoamides. The latter have been each transformed into the corresponding cyclic imide derivatives by treating with SOCl2. Alternatively, anhydrides have been reacted with methanolic KOH to obtain monomethyl ester derivatives which on reaction with aromatic amines in the presence of EDC. HCl and HOBt give cyclic imide derivatives. Reaction of monoacid monoamides independently, with SOCl 2 at 0-5°C give the monoamide monoester derivatives. Treatment of monoamide monoester of malic anhydride with NaBH4 leads to the unusual reduction of C=C grouping as well as the carbonyl group of the ester group to from monoamide monoalcohol of succinic anhydride. Preparation of monoamide monoalcohol of succinic anhydride can also be achieved by chemoselective reduction of monoamide monoester of malic anhydride with Mg turnings yielding monoamide monoester of succinic anhydride followed by reduction of the latter with NaBH4.

A facile and green synthesis of N-substituted imides

Anhydrides 1, 6 and 10 have been reacted, independently, with aromatic primary amines 2 in solid phase by simple physical grinding of reactants with p-toluenesulphonicacid as a catalyst to yield corresponding open chain derivatives, monoacid monoamides3,7 and 11 respectively. The latter have each been transformed into the corresponding cyclic derivatives, i.e. imides 5, 9 and 13 respectively in solid phase by simple physical grinding of each with K 2CO3, alkylating agent and tetrabutylammoniumbromide as a catalyst with short reaction times. These cyclic imides can also be obtained by physical grinding of each of 3, 7 and 11 with dicyclohexylcarbodimide as a dehydrating agent in solid phase.

HIV INHIBITORS

Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.

Synthesis of the major metabolites of Tolvaptan

Tolvaptan is a nonpeptide arginine vasopressin (AVP) V2-receptor antagonist and used in the treatment of heart failure, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion or other high-volume capacity of hyponatremia. The metab

Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1

The CD4 binding site on HIV-1 gp120 has been validated as a drug target to prevent HIV-1 entry to cells. Previously, we identified two small molecule inhibitors consisting of a 2,2,6,6-tetramethylpiperidine ring linked by an oxalamide to a p-halide-substituted phenyl group, which target this site, specifically, a cavity termed "Phe43 cavity". Here we use synthetic chemistry, functional assessment, and structure-based analysis to explore variants of each region of these inhibitors for improved antiviral properties. Alterations of the phenyl group and of the oxalamide linker indicated that these regions were close to optimal in the original lead compounds. Design of a series of compounds, where the tetramethylpiperidine ring was replaced with new scaffolds, led to improved antiviral activity. These new scaffolds provide insight into the surface chemistry at the entrance of the cavity and offer additional opportunities by which to optimize further these potential-next- generation therapeutics and microbicides against HIV-1.

Bicyclic guanidine-catalyzed direct asymmetric allylic addition of N-aryl alkylidene-succinimides

Enantio-enriched maleimides and succinimides that can be used to prepare aza-heterocycles with multiple chiral centers are obtained from the bicyclic guanidine-catalyzed direct asymmetric allylic addition of N-aryl alkylidene-succinimides to imines. NMR studies and deuterium-exchange experiments were used to study the intermediates in the reaction.